Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lixte Biotechnology Holdings, Inc. - Common Stock (NQ:LIXT)

3.140 +0.070 (+2.28%)
Streaming Delayed Price Updated: 11:45 AM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,883
Open 3.050
Bid (Size) 3.060 (100)
Ask (Size) 3.400 (200)
Prev. Close 3.070
Today's Range 3.050 - 3.230
52wk Range 0.6400 - 6.260
Shares Outstanding 5,704,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year
Via Investor Brand Network
Topics Intellectual Property
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes
Via Investor Brand Network

Performance

YTD
-18.2%
-18.2%
1 Month
+7.2%
+7.2%
3 Month
-19.5%
-19.5%
6 Month
-37.6%
-37.6%
1 Year
+159.5%
+159.5%

More News

Read More
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials
Via Investor Brand Network
Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership
Via Investor Brand Network
When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It
Via Investor Brand Network
Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming
Via Investor Brand Network
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
Via Investor Brand Network
Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy
Via Investor Brand Network
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships
Via Investor Brand Network
Building a New Cancer Care Ecosystem: Liora’s Proton Therapy and LIXTE’s Drug Pipeline in Synergy
Via Investor Brand Network
TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline
Via Investor Brand Network
Topics Intellectual Property
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research
Via Investor Brand Network
Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy
Via Investor Brand Network
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care
Via Investor Brand Network
BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary
Via Investor Brand Network
Topics Intellectual Property
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement
Via Investor Brand Network
BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy
Via Investor Brand Network
Topics Intellectual Property
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment
Via Investor Brand Network
InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment
Via Investor Brand Network
Topics Intellectual Property
MissionIRNewsBreaks –  LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment
Via Investor Brand Network
Topics Intellectual Property
Improving the Odds: How LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective
Via Investor Brand Network
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy
Via Investor Brand Network
BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit at Morehouse College
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) to Participate In DealFlow Discovery Conference
Via Investor Brand Network
Topics Intellectual Property
TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Engages IBN to Support Corporate Communications Strategy
Via Investor Brand Network
Topics Intellectual Property

Frequently Asked Questions

Is Lixte Biotechnology Holdings, Inc. - Common Stock publicly traded?
Yes, Lixte Biotechnology Holdings, Inc. - Common Stock is publicly traded.
What exchange does Lixte Biotechnology Holdings, Inc. - Common Stock trade on?
Lixte Biotechnology Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lixte Biotechnology Holdings, Inc. - Common Stock?
The ticker symbol for Lixte Biotechnology Holdings, Inc. - Common Stock is LIXT on the Nasdaq Stock Market
What is the current price of Lixte Biotechnology Holdings, Inc. - Common Stock?
The current price of Lixte Biotechnology Holdings, Inc. - Common Stock is 3.140
When was Lixte Biotechnology Holdings, Inc. - Common Stock last traded?
The last trade of Lixte Biotechnology Holdings, Inc. - Common Stock was at 04/01/26 11:45 AM ET
What is the market capitalization of Lixte Biotechnology Holdings, Inc. - Common Stock?
The market capitalization of Lixte Biotechnology Holdings, Inc. - Common Stock is 17.91M
How many shares of Lixte Biotechnology Holdings, Inc. - Common Stock are outstanding?
Lixte Biotechnology Holdings, Inc. - Common Stock has 18M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.